Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Biogen Inc (NASDAQ:BIIB) on Sunday, setting a price target of $350, which is approximately 28.52% above the present share price of $272.33.
Kulkarni expects Biogen Inc to post earnings per share (EPS) of $9.60 for the third quarter of 2020.
The current consensus among 27 TipRanks analysts is for a Moderate Buy rating of shares in Biogen, with an average price target of $310.68.
The analysts price targets range from a high of $392 to a low of $228.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $3.68 billion and a net profit of $1.98 billion. The company's market cap is $43.11 billion.
According to TipRanks.com, Canaccord Genuity analyst Sumant Kulkarni is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.6% and a 49.40% success rate.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp (OTC:SHCAY) in 1978 and is headquartered in Cambridge, MA.